Incidence and risk factors of VTE in patients with cervical cancer using the Korean national health insurance data

AbstractThis study investigated incidence and risk factors for venous thromboembolism (VTE) in patients with cervical cancer. We selected 49,514 patients newly diagnosed with cervical cancer from the Korean Health Insurance Review and Assessment Service databases. During the total follow-up period and first 6 months after initiation of primary treatments, incidence of VTE, and association of risk factors with VTE occurrence were evaluated according to primary treatments or no treatment, surgery, radiotherapy, and chemotherapy. VTE occurred in 1.15% of patients with cervical cancer. Regardless of the period after initiation of primary treatments, and of VTE, the incidence of thromboembolism was highest in chemotherapy. During the first 12 months, monthly incidence of VTE was highest in chemotherapy and decreased with time in all primary treatments. Compared with no treatment, VTE risk significantly increased for all primary treatments (surgery: HR 1.492; 95% CI 1.186–1.877) (radiotherapy: HR 2.275; 95% CI 1.813–2.855) (chemotherapy: HR 4.378; 95% CI 3.095–6.193) and for chemotherapy during the first 6 months (HR 3.394; 95% CI 2.062–5.588). In this cohort study, incidence and risk of VTE in patients with cervical cancer were the highest when chemotherapy was the primary cancer treatment, and incidence of VTE decreased with time.

Download Full-text

Glucose-lowering drug prescriptions in patients with newly diagnosed type 2 diabetes: statutory health insurance data from 2012 – 2016

10.1055/s-0039-1688177 ◽

2019 ◽

Author(s):

B Bongaerts ◽

B Kollhorst ◽

O Kuss ◽

I Pigeot ◽

W Rathmann

Keyword(s):

Type 2 Diabetes ◽

Health Insurance ◽

Statutory Health Insurance ◽

Drug Prescriptions ◽

Newly Diagnosed ◽

Health Insurance Data ◽

Glucose Lowering ◽

Lowering Drug ◽

Insurance Data

Download Full-text

Analysis of behavioral management for dental treatment in patients with dementia using the Korean National Health Insurance data

Journal of Dental Anesthesia and Pain Medicine ◽

10.17245/jdapm.2021.21.5.461 ◽

2021 ◽

Vol 21 (5) ◽

pp. 461

Author(s):

Taeksu Kim ◽

Seong In Chi ◽

Hyuk Kim ◽

Kwang-Suk Seo

Keyword(s):

Health Insurance ◽

National Health Insurance ◽

National Health ◽

Dental Treatment ◽

Behavioral Management ◽

Health Insurance Data ◽

Korean National Health Insurance ◽

Insurance Data

Download Full-text

Prevalence and Therapy Rates for Stuttering, Cluttering, and Developmental Disorders of Speech and Language: Evaluation of German Health Insurance Data

Frontiers in Human Neuroscience ◽

10.3389/fnhum.2021.645292 ◽

2021 ◽

Vol 15 ◽

Author(s):

Martin Sommer ◽

Andrea Waltersbacher ◽

Andreas Schlotmann ◽

Helmut Schröder ◽

Adam Strzelczyk

Keyword(s):

Health Insurance ◽

Developmental Disorders ◽

Treatment Patterns ◽

Newly Diagnosed ◽

Speech And Language ◽

Health Insurance Data ◽

Old Patients ◽

German Health ◽

Insurance Data ◽

Crude Prevalence

PurposeTo evaluate the prevalence and treatment patterns of speech and language disorders in Germany.MethodsA retrospective analysis of data collected from 32% of the German population, insured by the statutory German health insurance (AOK, Local Health Care Funds). We used The International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification (ICD-10 GM) codes for stuttering (F98.5), cluttering (F98.6), and developmental disorders of speech and language (F80) to identify prevalent and newly diagnosed cases each year. Prescription and speech therapy reimbursement data were used to evaluate treatment patterns.ResultsIn 2017, 27,977 patients of all ages were diagnosed with stuttering (21,045 males, 75% and 6,932 females, 25%). Stuttering prevalence peaks at age 5 years (boys, 0.89% and girls, 0.40%). Cluttering was diagnosed in 1,800 patients of all ages (1,287 males, 71.5% and 513 females, 28.5%). Developmental disorders of speech and language were identified in 555,774 AOK-insurants (61.2% males and 38.8% females). Treatment data indicate a substantial proportion newly diagnosed stuttering individuals receive treatment (up to 45% of 6-year-old patients), with slightly fewer than 20 sessions per year, on average. We confirmed a previous study showing increased rates of atopic disorders and neurological and psychiatric comorbidities in individuals with stuttering, cluttering, and developmental disorders of speech and language.ConclusionThis is the first nationwide study using health insurance data to analyze the prevalence and newly diagnosed cases of a speech and language disorder. Prevalence and gender ratio data were consistent with the international literature. The crude prevalence of developmental disorders of speech and language increased from 2015 to 2018, whereas the crude prevalence for stuttering remained stable. For cluttering, the numbers were too low to draw reliable conclusions. Proportional treatment allocation for stuttering peaked at 6 years of age, which is the school entrance year, and is later than the prevalence peak of stuttering.

Download Full-text